Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul Sekhri
AddedFeb 13, 2024
UpdatedMay 31, 2026
Paul Sekhri

Paul Sekhri

Board Member, Ipsen

CrunchbaseLinkedInThe Org

Paul Sekhri's Career

Ipsen
Ipsen

Boulogne-Billancourt, Hauts-de-Seine, FR

Board Member· Board
Spring Discovery
Spring Discovery

San Carlos, CA, US

Board Member· Board
eGenesis
eGenesis

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul Sekhri's Career

Ipsen
Ipsen
Public$22M5.7k1929Boulogne-Billancourt, Hauts-de-Seine, FR
Board Member· Board

Leadership at Ipsen

Michele OllierMichele OllierBoard Member
Karen WittsKaren WittsBoard Member
Henri BeaufourHenri BeaufourFounder
David LoewDavid LoewBoard Member
Marc De GaridelMarc De GaridelBoard Member
Antoine FlochelAntoine FlochelBoard Member

Similar to Ipsen

SanofiSanofiParis, Paris, FRPharmaceuticalsest. 1973SanofiParis, Paris, FR · est. 1973

Sanofi, a global French pharmaceutical firm, manufactures prescription drugs and vaccines, specializing in various medical fields.

Public · $610M91.6k
Bristol Myers SquibbBristol Myers SquibbNew York City, NY, USPharmaceuticalsest. 1887Bristol Myers SquibbNew York City, NY, US · est. 1887

Leading American pharmaceutical company specializing in research and development.

Public · $10.6B34.3k
Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
UCBUCBCity of Brussels, Flemish Brabant, BEPharmaceuticalsest. 1928UCBCity of Brussels, Flemish Brabant, BE · est. 1928

Belgium-based UCB SA is a global biopharmaceutical firm specializing in CNS disorders and inflammatory diseases.

Public · $195.3M7.6k
Spring Discovery
Spring Discovery
Series B$22.3M292017San Carlos, CA, US
Board Member· Board

Leadership at Spring Discovery

Ben KamensBen KamensFounder

Similar to Spring Discovery

OccamzRazorOccamzRazorSan Francisco, CA, USDrug Discoveryest. 2015OccamzRazorSan Francisco, CA, US · est. 2015

OccamzRazor: Unveiling Parkinson's Disease treatments through dynamic machine learning mapping.

Series A · $12.4M35
BioAge LabsBioAge LabsRichmond, CA, USDrug Developmentest. 2015BioAge LabsRichmond, CA, US · est. 2015

BioAge Labs builds software and services for its target customers and markets.

Series C · $123.9M175
Regenerative BioRegenerative BioCambridge, MA, USPharmaceuticalsest. 2020Regenerative BioCambridge, MA, US · est. 2020

Regenerative Bio: AI-driven biotech firm pioneering anti-aging solutions through pharmaceutical tech.

Angel · $10M13
InsitroInsitroSouth San Francisco, CA, USDrug Discoveryest. 2018InsitroSouth San Francisco, CA, US · est. 2018

Insitro: Leveraging machine learning for data-driven drug discovery and development.

Series C · $643M295
eGenesis
eGenesis
Series C$265M1052015Cambridge, MA, US
Board Member· Board

Leadership at eGenesis

Isaac CiechanoverIsaac CiechanoverBoard Member
Bob MoreBob MoreBoard Member
Al WiegmanAl WiegmanBoard Member
Boris NikolicBoris NikolicBoard Member
Julie SunderlandJulie SunderlandBoard Member
Mike CurtisMike CurtisCEO

Similar to eGenesis

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
InGeneronInGeneronHouston, TX, USRegenerative Therapiesest. 2006InGeneronHouston, TX, US · est. 2006

InGeneron: A multinational biotech firm unlocking patient healing through innovative regenerative therapies.

Series D · $51M32
ExogenesisExogenesisBillerica, MA, USMedical Devicesest. 2005ExogenesisBillerica, MA, US · est. 2005

Exogenesis Corp., based in Billerica, US, develops and processes implantable medical devices.

Seed · $7.8M17
InscriptaInscriptaBoulder, CO, USGenome Engineeringest. 2015InscriptaBoulder, CO, US · est. 2015

Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.

Series A · $463.9M178

Paul Sekhri's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoBrian KimBrian KimBoard Member · Kakao

People Similar to Paul Sekhri

Paul J SekhriPaul J SekhriCo-Founder · Aditum BioCody JamesCody JamesFounder · Open XPaul ShenPaul ShenFounder · TVU NetworksChip DoughertyChip DoughertyCEO · Vivasc TherapeuticsMichael ShleiferMichael ShleiferCo-Founder · SprimJeffrey ClelandJeffrey ClelandBoard Member · Exicure